Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects.

Shen H, Holenarsipur VK, Mariappan TT, Drexler DM, Cantone JL, Rajanna P, Singh Gautam S, Zhang Y, Gan J, Shipkova PA, Marathe P, Humphreys WG.

J Pharmacol Exp Ther. 2019 Jan;368(1):136-145. doi: 10.1124/jpet.118.252643. Epub 2018 Oct 25.

PMID:
30361237
2.

In Vitro Stimulation of Multidrug Resistance-Associated Protein 2 Function Is Not Reproduced In Vivo in Rats.

Gilibili RR, Kurawattimath V, Murali BV, Lai Y, Mariappan TT, Shen H, Chatterjee S.

Pharmaceutics. 2018 Aug 8;10(3). pii: E125. doi: 10.3390/pharmaceutics10030125.

3.

Effect of pretreatment regimens of 1-aminobenzotriazole on metabolism and gastric emptying of probe compounds in rat.

Padmanabhan S, Kaur H, Rao A, Saxena A, Gupta YK, Mariappan TT, Holenarsipur VK.

Xenobiotica. 2019 Jun;49(6):646-654. doi: 10.1080/00498254.2018.1489166. Epub 2018 Sep 7.

PMID:
29898636
4.

Endogenous Biomarkers to Assess Drug-Drug Interactions by Drug Transporters and Enzymes.

Mariappan TT, Shen H, Marathe P.

Curr Drug Metab. 2017 Oct 16;18(8):757-768. doi: 10.2174/1389200218666170724110818. Review.

PMID:
28738769
5.

Unmasking the Role of Uptake Transporters for Digoxin Uptake Across the Barriers of the Central Nervous System in Rat.

Taskar KS, Mariappan TT, Kurawattimath V, Singh Gautam S, Radhakrishna Mullapudi TV, Sridhar SK, Kallem RR, Marathe P, Mandlekar S.

J Cent Nerv Syst Dis. 2017 Mar 15;9:1179573517693596. doi: 10.1177/1179573517693596. eCollection 2017.

6.

Coproporphyrin-I: A Fluorescent, Endogenous Optimal Probe Substrate for ABCC2 (MRP2) Suitable for Vesicle-Based MRP2 Inhibition Assay.

Gilibili RR, Chatterjee S, Bagul P, Mosure KW, Murali BV, Mariappan TT, Mandlekar S, Lai Y.

Drug Metab Dispos. 2017 Jun;45(6):604-611. doi: 10.1124/dmd.116.074740. Epub 2017 Mar 21.

PMID:
28325716
7.

Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity.

Dudhgaonkar S, Ranade S, Nagar J, Subramani S, Prasad DS, Karunanithi P, Srivastava R, Venkatesh K, Selvam S, Krishnamurthy P, Mariappan TT, Saxena A, Fan L, Stetsko DK, Holloway DA, Li X, Zhu J, Yang WP, Ruepp S, Nair S, Santella J, Duncia J, Hynes J, McIntyre KW, Carman JA.

J Immunol. 2017 Feb 1;198(3):1308-1319. doi: 10.4049/jimmunol.1600583. Epub 2016 Dec 21.

8.

Role of hepatic blood flow and metabolism in the pharmacokinetics of ten drugs in lean, aged and obese rats.

Subramanian M, Kurawattimath V, Pocha K, Freeden C, Rao I, Mariappan TT, Marathe PH, Vikramadithyan RK, Abraham P, Kulkarni CP, Katnapally P, Nutakki R, Paruchury S, Bhutani P, Mandlekar S.

Xenobiotica. 2014 Dec;44(12):1108-16. doi: 10.3109/00498254.2014.932470. Epub 2014 Jun 20.

PMID:
24947446
9.

Estimation of the unbound brain concentration of P-glycoprotein substrates or nonsubstrates by a serial cerebrospinal fluid sampling technique in rats.

Mariappan TT, Kurawattimath V, Gautam SS, Kulkarni CP, Kallem R, Taskar KS, Marathe PH, Mandlekar S.

Mol Pharm. 2014 Feb 3;11(2):477-85. doi: 10.1021/mp400436d. Epub 2014 Jan 9.

PMID:
24380373
10.

Insight into tissue unbound concentration: utility in drug discovery and development.

Mariappan TT, Mandlekar S, Marathe P.

Curr Drug Metab. 2013 Mar;14(3):324-40. Review.

PMID:
23167621
11.

A modified serial blood sampling technique and utility of dried-blood spot technique in estimation of blood concentration: application in mouse pharmacokinetics.

Kurawattimath V, Pocha K, Mariappan TT, Trivedi RK, Mandlekar S.

Eur J Drug Metab Pharmacokinet. 2012 Mar;37(1):23-30. doi: 10.1007/s13318-011-0066-5. Epub 2011 Sep 25. Erratum in: Eur J Drug Metab Pharmacokinet. 2011 Dec;36(4):263.

PMID:
21948266
12.

High-performance liquid chromatographic method for the simultaneous estimation of the key intermediates of duloxetine.

Soni P, Mariappan TT, Banerjee UC.

Talanta. 2005 Oct 31;67(5):975-8. doi: 10.1016/j.talanta.2005.04.020.

PMID:
18970267
15.

Novel anti-tuberculosis FDC formulations without reduced bioavailability of rifampicin: from concept to market.

Singh S, Mariappan TT, Bhutani H.

Int J Tuberc Lung Dis. 2005 Jun;9(6):701-2. No abstract available.

PMID:
15971403
16.

Overestimation of rifampicin during colorimetric analysis of anti-tuberculosis products containing isoniazid due to formation of isonicotinyl hydrazone.

Mariappan TT, Jindal KC, Singh S.

J Pharm Biomed Anal. 2004 Nov 19;36(4):905-8. Erratum in: J Pharm Biomed Anal. 2005 Apr 29;37(5):1185.

PMID:
15533688
17.

Interference of isonicotinyl hydrazone in the microbiological analysis of rifampicin from anti-tuberculosis FDC products containing isoniazid.

Mariappan TT, Geetha T, Pandey R, Jindal KC, Singh S.

J Pharm Biomed Anal. 2004 Nov 15;36(3):643-7. Erratum in: J Pharm Biomed Anal. 2005 Apr 29;37(5):1185.

PMID:
15522543
18.
20.

Regional gastrointestinal permeability of rifampicin and isoniazid (alone and their combination) in the rat.

Mariappan TT, Singh S.

Int J Tuberc Lung Dis. 2003 Aug;7(8):797-803.

PMID:
12921157

Supplemental Content

Loading ...
Support Center